Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 10,000 Shares

Knight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri sold 10,000 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of C$5.72, for a total value of C$57,200.00.

Amal Khouri also recently made the following trade(s):

• On Monday, June 10th, Amal Khouri sold 20,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.80, for a total value of C$116,022.00.

Knight Therapeutics Stock Performance

Shares of GUD stock traded down C$0.01 on Wednesday, hitting C$5.71. 20,948 shares of the stock traded hands, compared to its average volume of 68,072. The company’s fifty day moving average is C$5.81 and its 200 day moving average is C$5.59. Knight Therapeutics Inc. has a 1-year low of C$4.35 and a 1-year high of C$6.22. The company has a market capitalization of C$578.88 million, a PE ratio of -35.75, a PEG ratio of -1,013.50 and a beta of 0.46. The company has a debt-to-equity ratio of 9.20, a current ratio of 3.34 and a quick ratio of 1.79.

Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, May 9th. The company reported C($0.04) earnings per share for the quarter, missing the consensus estimate of C$0.02 by C($0.06). Knight Therapeutics had a negative net margin of 5.25% and a negative return on equity of 2.21%. The business had revenue of C$86.60 million for the quarter, compared to the consensus estimate of C$80.27 million. On average, equities research analysts predict that Knight Therapeutics Inc. will post 0.0303448 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GUD. Stifel Nicolaus lifted their price objective on shares of Knight Therapeutics from C$5.40 to C$5.75 in a research note on Friday, May 10th. Royal Bank of Canada raised their price objective on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd. Finally, Raymond James upped their target price on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an “outperform” rating in a research note on Wednesday, March 6th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.